Eris Lifesciences Ltd (ERIS) AI Stock Analysis

• Market Cap: ₹228.36B
• Dividend Yield: 0.44%
• Average Volume (3M): 4.21K
• Price to Earnings (P/E): 59.0
• Beta (1Y): 0.50
• Revenue Growth: 30.27%
• EPS Growth: 1.69%
• Country: IN
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 8.65
• Shares Outstanding: 136,206,790
• 10 Day Avg. Volume: 1,651
• 30 Day Avg. Volume: 4,210
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,926.00
• Price Target Upside: 14.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 72 Outperform
• Price Target: ₹1,926.00 ▲(14.88% Upside)

Eris Lifesciences Ltd scores well due to strong financial performance and positive technical indicators. However, its high P/E ratio and low dividend yield suggest potential overvaluation, weighing down the overall score.

Positive Factors

Revenue Growth

Eris Lifesciences has shown impressive revenue growth, indicating strong market demand and effective sales strategies in key therapeutic areas.

Operational Efficiency

Strong EBIT and EBITDA margins highlight Eris's ability to manage costs effectively, ensuring sustainable profitability and competitive positioning.

Product Portfolio

Eris's focus on high-growth therapeutic areas ensures a strong product portfolio that aligns with market needs, supporting long-term revenue growth.

Negative Factors

Cash Flow Volatility

Volatile cash flow can impact Eris's ability to invest consistently in growth opportunities, potentially affecting long-term strategic initiatives.

Decreasing Cash Reserves

Decreasing cash reserves could limit Eris's financial flexibility, potentially constraining its ability to respond to market changes or invest in new projects.

Net Profit Margin Fluctuations

Fluctuating net profit margins suggest challenges in maintaining consistent profitability, which could affect investor confidence and long-term financial health.

Eris Lifesciences Ltd Business Overview & Revenue Model

Company Description

Eris Lifesciences Ltd (ERIS) is an Indian pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of branded pharmaceutical products. The company focuses on therapeutic areas such as cardiology, diabetes, gastroenterology, orthopaedics, and gynaecology. Eris Lifesciences is known for its strong presence in the chronic and lifestyle-related disorders segment, leveraging its research and development capabilities to innovate and deliver effective healthcare solutions.

How the Company Makes Money

Eris Lifesciences Ltd generates revenue through the sale of its branded pharmaceutical products across various therapeutic segments. The company markets its products directly to healthcare professionals, leveraging a robust sales force to promote its offerings. Revenue streams are primarily driven by domestic sales within India, with a focus on high-growth therapeutic areas like cardiology and diabetes management. Eris Lifesciences also engages in strategic partnerships and collaborations to enhance its product portfolio and market reach, contributing to its financial performance. The company invests in research and development to create differentiated products, which helps maintain competitive advantage and drive sales.

Eris Lifesciences Ltd Financial Statement Overview

Summary

Eris Lifesciences Ltd demonstrates solid financial health with strong revenue growth and efficient cost management. The balance sheet is healthy, reflecting effective resource utilization, though cash flow volatility and decreasing cash reserves warrant attention.

Income Statement

Eris Lifesciences Ltd has shown impressive revenue growth over the years, with a significant jump from 2024 to 2025. The Gross Profit Margin remains strong, indicating efficient cost management. However, the Net Profit Margin has shown some fluctuations, indicating potential areas for improvement. The EBIT and EBITDA margins are robust, demonstrating solid operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a solid equity base. The Debt-to-Equity Ratio is manageable, suggesting prudent financial leverage. The Return on Equity is strong, reflecting effective resource utilization. However, the decrease in cash and equivalents over the years may need monitoring.

Cash Flow

Eris Lifesciences Ltd has demonstrated strong growth in Operating Cash Flow, which supports its Net Income. The Free Cash Flow has seen significant improvement, indicating efficient capital expenditure management. However, the fluctuations in Free Cash Flow over the years highlight potential volatility in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	28.86B	28.79B	19.91B	13.26B	16.62B	11.93B
Gross Profit	17.57B	13.01B	9.95B	10.65B	13.09B	9.51B
EBITDA	10.29B	10.17B	6.99B	5.11B	5.48B	4.39B
Net Income	3.52B	3.52B	3.92B	4.06B	3.82B	3.55B
Balance Sheet
Total Assets	70.33B	70.33B	70.49B	22.72B	36.67B	18.35B
Cash, Cash Equivalents and Short-Term Investments	2.28B	2.28B	13.39B	1.77B	892.43M	522.69M
Total Debt	24.78B	24.78B	27.81B	844.07M	8.77B	67.77M
Total Liabilities	37.61B	37.61B	38.27B	3.64B	14.47B	2.58B
Stockholders Equity	28.54B	28.54B	25.86B	19.08B	21.96B	15.76B
Cash Flow
Free Cash Flow	0.00	9.10B	3.57B	2.57B	-5.50B	3.50B
Operating Cash Flow	0.00	10.65B	4.86B	3.78B	2.92B	3.75B
Investing Cash Flow	0.00	-799.70M	-18.55B	-3.20B	-9.82B	-3.23B
Financing Cash Flow	0.00	-8.81B	13.80B	-446.99M	6.88B	-823.95M

Eris Lifesciences Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1676.60
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ERIS, the sentiment is Neutral. The current price of 1676.6 is below the 20-day moving average (MA) of 1747.66, below the 50-day MA of 1750.38, and above the 200-day MA of 1496.20, indicating a neutral trend. The MACD of -11.94 indicates Positive momentum. The RSI at 36.01 is Neutral, neither overbought nor oversold. The STOCH value of 13.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ERIS.

Eris Lifesciences Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERIS	72 Outperform	₹228.36B	58.98		0.44%	30.27%	1.69%
Sector *	51 Neutral	$7.93B	-0.35	-43.30%	2.25%	22.54%	-2.22%
EMCURE	―	₹255.43B	34.26		―	―	―
GLAND	69 Neutral	₹332.95B	43.23		0.89%	-2.34%	6.64%
GLAXO	66 Neutral	₹470.09B	49.47		1.94%	6.65%	48.47%
GLENMARK	54 Neutral	₹601.29B	79.77		0.12%	10.99%	―
SANOFICONR	―	₹119.65B	59.81		―	―	―